

Reply Letter – Side effects to BNT162b2 can be severe

I.N. MARTÍNEZ-SALAZAR

Military Central Hospital, SEDENA, CDMX, México

Dear Author,

First of all, we would like to thank the authors for their comments.

Participants were included in the study, once they have received two doses of BN162b2 vaccine. The digital survey, searched for side effects described by the participants after each dose. If an option of frequent side effects was not listed (i.e., headache, fever, etcetera), the option “others, please describe” as an empty box was provided. Not severe side effects were described among participants.

It is important to remark, that this population is a healthy military population; 80% of participants did not have any comorbidities. Nevertheless, there were participants who presented overweight but no other medical conditions. On the other hand, hospitalization was not required by any military personnel within this population with regard of side effects.

Furthermore, the digital survey was answered by participants between the 28-61 days after the first dose, and 7-40 days after the second dose, with a median of 14 days.

Finsterer et al¹ included 19 participants, only 4 were reported with the BTN16b2 vaccine, side effects were presented 3 hours to 14 days after the first dose. Side effects related with vaccination, such as Bell paralysis and other immunological diseases have been described between 3-4 days after vaccination^{2,3}.

With regard of cerebrovascular events produced by BTN162b2, Schultz et al⁴ estimated 0.11 cases of 100,000, so it is unlikely to find any CVE in our population, likewise, with the Acute Disseminated Encephalomyelitis (ADEM)⁵ considering that our participants consisted in healthy military personnel with a most predominant age between 21 to 59 years old.

Once again, we appreciate your comments and hope this letter answer your questions.

Conflict of Interest

The author declares that he has no conflict of interests.

References

- 1) Finsterer J, Scorza FA, Scorza CA. Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. *Clinics (Sao Paulo)* 2021; 76: e3286.
- 2) Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. *Int J Infect Dis* 2021; 111: 310-312.
- 3) Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. *Vaccines (Basel)* 2021; 9: 435.
- 4) Schulz JB, Berlitz P, Diener HC, Gerloff C, Greinacher A, Klein C, Petzold GC, Piccininni M, Poli S, Röhrig R, Steinmetz H, Thiele T, Kurth T; German Society of Neurology SARS-CoV-2 Vaccination Study Group. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. *Ann Neurol* 2021; 90: 627-639.
- 5) Vogrig A, Janes F, Gigli GL, Curcio F, Negro ID, D'Agostini S, Fabris M, Valente M. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. *Clin Neurol Neurosurg* 2021; 208: 106839.